Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Houda Mahayni
Observed names:
H Mahayni,
H. Mahayni
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Elan Pharmaceuticals, Inc. (Ireland)
OpenAlex ID:
A5042597635
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
2013
·
Thomas M. Herndon
, Albert Deisseroth
, et al.
·
Clinical Cancer Research
·
265
Draft Guidance for Industry Extended-Release Solid Oral Dosage Forms
1997
·
Henry Malinowski
, Patrick Marroum
, et al.
·
Advances in experimental medicine and biology
·
150
FDA Guidance for Industry 1 Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations
1997
·
Henry Malinowski
, Patrick Marroum
, et al.
·
Dissolution Technologies
·
94
PDF
Evaluation of “External” Predictability of an In Vitro–In Vivo Correlation for an Extended‐Release Formulation Containing Metoprolol Tartrate
2000
·
H. Mahayni
, G.S. Rekhi
, et al.
·
Journal of Pharmaceutical Sciences
·
36
A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
1999
·
I Mahmood
, H Mahayni
·
PubMed
·
12
Megestrol acetate in AIDS-related cachexia.
1991
·
H Mahayni
, J R Minor
·
PubMed
·
4
Antiretroviral activity of naloxone and naltrexone.
1991
·
H Mahayni
, J R Minor
·
PubMed
·
2
Show more works
View as search
Works count:
7
Citation count:
563
H-index:
5
I10-index:
5
Year
Topic
Type